Dogwood Therapeutics, Inc. Retained Earnings
Dogwood Therapeutics, Inc. (DWTX) had Retained Earnings of -$124.59 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$124.59M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$113.06M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$108.08M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$104.30M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$124.59M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$113.06M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$108.08M 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$104.30M 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$88.55M 10-Q · filed 2025-08-13 |
| 2025-03-31 | -$84.74M 10-Q · filed 2025-05-09 |
| 2024-12-31 | -$73.82M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$66.09M 10-Q · filed 2024-11-08 |
| 2024-06-30 | -$63.81M 10-Q · filed 2024-08-09 |
| 2024-03-31 | -$62.76M 10-Q · filed 2024-05-10 |
| 2023-12-31 | -$61.47M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$60.37M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$59.13M 10-Q · filed 2023-08-11 |
| 2023-03-31 | -$57.69M 10-Q · filed 2023-05-12 |
| 2022-12-31 | -$56.17M 10-K/A · filed 2024-03-08 |
| 2022-09-30 | -$54.13M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$51.55M 10-Q · filed 2022-08-12 |
| 2022-03-31 | -$47.89M 10-Q · filed 2022-05-13 |
| 2021-12-31 | -$43.93M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$39.41M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$35.30M 10-Q · filed 2021-08-13 |
| 2021-03-31 | -$31.02M 10-Q · filed 2021-05-14 |
| 2020-12-31 | -$27.97M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |